147 related articles for article (PubMed ID: 38707739)
1. Factors Associated With Prescription of Systemic Therapy in Real-world Patients With Metastatic Renal Cell Cancer Managed in a Rural Region.
Nieder C; Stanisavljevic L; Haukland EC
Cancer Diagn Progn; 2024; 4(3):250-255. PubMed ID: 38707739
[TBL] [Abstract][Full Text] [Related]
2. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.
Mathieu R; Pignot G; Ingles A; Crepel M; Bigot P; Bernhard JC; Joly F; Guy L; Ravaud A; Azzouzi AR; Gravis G; Chevreau C; Zini L; Lang H; Pfister C; Lechevallier E; Fais PO; Berger J; Vayleux B; Roupret M; Audenet F; Descazeaud A; Rigaud J; Machiels JP; Staehler M; Salomon L; Ferriere JM; Kleinclauss F; Bensalah K; Patard JJ
Urol Oncol; 2015 Aug; 33(8):339.e9-15. PubMed ID: 26087971
[TBL] [Abstract][Full Text] [Related]
3. Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance.
Shuch B; La Rochelle JC; Wu J; Klatte T; Riggs SB; Kabbinavar F; Belldegrun AS; Pantuck AJ
Cancer; 2008 Sep; 113(6):1324-31. PubMed ID: 18661529
[TBL] [Abstract][Full Text] [Related]
4. Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status.
Carril-Ajuria L; Colomba E; Romero-Ferreiro C; Cerbone L; Ratta R; Barthelemy P; Vindry C; Fléchon A; Cherifi F; Boughalem E; Linassier C; Fornarini G; Rebuzzi SE; Gross-Goupil M; Saldana C; Martin-Soberón M; de Velasco G; Manneh R; Pernaut C; Sanchez de Torre A; Flippot R; Escudier B; Albiges L
Eur J Cancer; 2023 Feb; 180():21-29. PubMed ID: 36527973
[TBL] [Abstract][Full Text] [Related]
5. Patterns of care for metastatic renal cell carcinoma in Australia.
Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Andrews M; Davis ID; Azad AA; Rosenthal M; Wong S; Johnstone A; Gibbs P; Tran B
BJU Int; 2015 Oct; 116 Suppl 3():36-41. PubMed ID: 26204961
[TBL] [Abstract][Full Text] [Related]
6. Eastern Spanish experience with nivolumab in metastatic renal cell carcinoma.
José JM; Jose M; Silverio R; Federico V; Isabel C; Martin OA; Inmaculada B; Cristina C; Julia HC; Dolores TM; Jose G; Paola P; Nieves DP; Vicent A; Sara B; Sara M; Julián L; Manuel S; Del Carmen MM; Ángel CM; Vicente G
Clin Transl Oncol; 2020 Sep; 22(9):1517-1523. PubMed ID: 32048159
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers.
Dragomir A; Nazha S; Tanguay S; Breau RH; Bhindi B; Rendon RA; Kapoor A; Hotte SJ; Basappa N; Fairey A; So AI; Kollmannsberger C; Finelli A; Hansen A; Canil C; Heng D; Lattouf JB; Bjarnason G; Power N; Pouliot F; Wood LA
Eur Urol Focus; 2022 Nov; 8(6):1703-1710. PubMed ID: 34736870
[TBL] [Abstract][Full Text] [Related]
8. Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study.
Chen J; Ye W; Jiang W; Li X; Liu R; Lin B; Xiang J; Tian W; Bai J; Zuo T; Lin B; Guo Y; Zheng S
Transl Androl Urol; 2021 Mar; 10(3):1321-1331. PubMed ID: 33850766
[TBL] [Abstract][Full Text] [Related]
9. Impact of palliative chemotherapy and best supportive care on overall survival and length of hospitalization in patients with incurable Cancer: a 4-year single institution experience in Japan.
Murakawa Y; Sakayori M; Otsuka K
BMC Palliat Care; 2019 Jun; 18(1):45. PubMed ID: 31159782
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice.
Kancharla H; Gundu N; Pathak N; Vandidassane I; Khurana S; Pushpam D; Jain D; Kumar S; Pathy S; Mohan A; Malik PS
Curr Probl Cancer; 2020 Jun; 44(3):100550. PubMed ID: 31987521
[TBL] [Abstract][Full Text] [Related]
11. The relationship between Eastern Cooperative Oncology Group performance status and healthcare resource utilization among patients with advanced or metastatic colorectal, lung or gastric cancer.
Hess LM; Smith D; Cui ZL; Montejano L; Liepa AM; Schelman W; Bowman L
J Drug Assess; 2020 Dec; 10(1):10-17. PubMed ID: 33403155
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
Mani S; Todd MB; Katz K; Poo WJ
J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
[TBL] [Abstract][Full Text] [Related]
13. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
[TBL] [Abstract][Full Text] [Related]
14. Favorable outcome in elderly Asian patients with metastatic renal cell carcinoma treated with everolimus: the Osaka Urologic Oncology Group.
Inamoto T; Azuma H; Nonomura N; Nakatani T; Matsuda T; Nozawa M; Ueda T; Kinoshita H; Nishimura K; Kanayama HO; Miki T; Tomita Y; Yoshioka T; Tsujihata M; Uemura H
Asian Pac J Cancer Prev; 2014; 15(4):1811-5. PubMed ID: 24641414
[TBL] [Abstract][Full Text] [Related]
15. The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4.
Crosara Teixeira M; Marques DF; Ferrari AC; Alves MF; Alex AK; Sabbaga J; Hoff PM; Riechelmann RP
Clin Colorectal Cancer; 2015 Mar; 14(1):52-7. PubMed ID: 25442812
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy with toripalimab for lung adenocarcinoma in a real-world patient with an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 4: a case report.
Xue Y; Zheng K; Xue J
Ann Palliat Med; 2021 Sep; 10(9):10114-10123. PubMed ID: 34628932
[TBL] [Abstract][Full Text] [Related]
17. Patterns of Care in Patients with Metastatic Renal Cell Carcinoma Among a U.S. Payer Population with Commercial or Medicare Advantage Membership.
Miller LA; Stemkowski S; Saverno K; Lane DC; Tao Z; Hackshaw MD; Loy B
J Manag Care Spec Pharm; 2016 Mar; 22(3):219-26. PubMed ID: 27003551
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach.
Liu WK; Lam JM; Butters T; Grant M; Jackson-Spence F; Bex A; Powles T; Szabados B
World J Urol; 2020 Dec; 38(12):3199-3205. PubMed ID: 32128610
[TBL] [Abstract][Full Text] [Related]
19. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status.
Alessi JV; Ricciuti B; Jiménez-Aguilar E; Hong F; Wei Z; Nishino M; Plodkowski AJ; Sawan P; Luo J; Rizvi H; Carter BW; Heymach JV; Altan M; Hellmann M; Awad M
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753547
[TBL] [Abstract][Full Text] [Related]
20. Deferred systemic therapy in patients with metastatic renal cell carcinoma.
Mitchell AP; Hirsch BR; Harrison MR; Abernethy AP; George DJ
Clin Genitourin Cancer; 2015 Jun; 13(3):e159-66. PubMed ID: 25770767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]